Galectin Therapeutics 3Q 2026: EPS ($0.04) — 10-Q Summary

Galectin Therapeutics (GALT) reported no revenue for Q3 2026, with a net loss of $3.57M, improved from $8.22M YoY. EPS loss narrowed to $0.04 from $0.13. R&D costs fell 40% due to reduced activity. The company has $11.7M in cash and expects funding through June 2027. It filed a Phase 3 protocol with the FDA and is exploring partnerships.

Original reporting
Published Nov 16, 2026, 1:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 1:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Galectin Therapeutics 3Q 2026: EPS ($0.04) — 10-Q Summary — source image
Decision brief

The 30-second read

$GALTNeutralLow
01

Why it matters

The filing provides the first public numbers for the quarter, highlighting cost reductions and cash runway through mid‑2027.

02

Market read

Micro‑cap biotech earnings with modest loss improvement; limited immediate trading impact.

03

What to watch

Potential upcoming FDA decision on belapectin could be a larger catalyst than current earnings.

Relevance 6/10Novelty 6/10Timing: released today

Background

Galectin Therapeutics filed its Q3 2026 10‑Q, reporting no revenue and a narrowed net loss.

Company-level read

Ticker impact

$GALTNeutralMedium confidence
Context

10-Q shows net loss narrowed to $3.57M and EPS loss to $0.04, new quarterly financials.

Expected impact

slight pressure as investors weigh loss against narrowing trend

Evidence & confidence

Micro‑cap biotech with no revenue; loss reduction is positive but magnitude is small, likely limited price move.

Market effects

Biotech sector may see modest confidence boost from loss narrowing but no broader impact.

US biotech micro‑caps could see slight uptick.

Limited to investors tracking small‑cap biotech earnings.

Counterpoint

Despite loss narrowing, continued cash burn and no product revenue suggest caution.

Key entities

  • Galectin Therapeutics Inc.

    US‑listed biotech developing belapectin.

Related articles

$GALTMed

Galectin Therapeutics Reports September 30, 2026 Financial Results and Provides Business Update

GALECTIN THERAPEUTICS INC (GALT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Galectin Therapeutics Reports September 30, 2026 Financial Results and Provides Business Update NORCROSS, Ga., November 16, 2026 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today

$GALTMedAI 8/10

Galectin Therapeutics Inc.: Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update

Galectin Therapeutics (NASDAQ:GALT) reported Q2 2026 results for the three months ended June 30, 2026 and said it reached agreement with the FDA on Phase 3 belapectin trial elements for MASH cirrhosis and portal hypertension, targeting protocol submission in 3Q 2026. Cash was $13.2M; net loss was $9.2M ($0.14/share). Chairman Uihlein converted about $105.8M debt into 34.4M shares.

$GALTMed

Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update

GALECTIN THERAPEUTICS INC (GALT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update NORCROSS, Ga., August 14, 2026 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reporte

$GALTMedAI 8/10

Galectin Therapeutics Inc.: Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet

Galectin Therapeutics (NASDAQ: GALT) said Chairman Richard E. Uihlein converted all outstanding principal and accrued interest under five line-of-credit facilities into common stock effective July 31, 2026. The deal eliminated about $105.8 million of debt (about $91.0 million principal, $14.8 million interest) and issued 34,376,167 shares at a blended $3.07 conversion price. A sixth $10 million facility remains undrawn.